tirzepatide panama JPM26: Eli Lilly's obesity drugs target commercial and governmental access Tirzepatide is getting attention for

Driven by the GLP-1 revolution the extraordinary commercial success of glucagon-like peptide-1 receptor agonist drugs for diabetes and obesity the market was worth USD 84.2 billion in 2025 and is expected to grow at a CAGR of 14.74% to reach USD 196.5 billion by 2031

Reddy's Laboratories, Cipla, and Lupin have publicly disclosed active semaglutide development programs, creating a robust and rapidly growing demand base for third-party API supply

Lets compare Noom and Weight Watchers in 2026looking at program structure, GLP-1 options, pricing, and long-term supportso you can decide which approach best fits your goals

For the hypothyroid-specific angle, see our Can You Use Weight Loss Injections With Underactive Thyroid